HIVAX is under clinical development by GeneCure Biotechnologies and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase II drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HIVAX’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HIVAX (replication-defective HIV-1 vaccine) is under development for the treatment of HIV-1 infections. The drug candidate is administered through subcutaneous route. It is developed based on lentiviral-based gene transfer technology.
GeneCure Biotechnologies overview
GeneCure Biotechnologies (GeneCure), formerly GeneCure is a biotechnology company that focuses on the development of gene based technology to treat genetic and acquired human diseases. The company offers products such as Hivax and SimVec. Its Hivax is a patented replication-defective HIV-1 vaccine which stimulates cellular and antibody immune responses in mouse and primate models. GeneCure also develops patented gene transfer technology SimVec based on a primate lentivirus which delivers genes into primary human cells without causing harm to humans. The company also uses its novel gene transfer technology to develop treatments for life-threatening human diseases including genetic diseases, infectious diseases, and cancers. It provides contract manufacturing services. GeneCure is headquartered in Norcross, Georgia, the US.
For a complete picture of HIVAX’s drug-specific PTSR and LoA scores, buy the report here.